Your session is about to expire
← Back to Search
CDK4/6 Inhibitor
Palbociclib + Sasanlimab for Kidney Cancer
Phase 1 & 2
Recruiting
Led By Ramaprasad Srinivasan, M.D.
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age >= 18 years
Adequate renal and hepatic function at screening including Serum creatinine <= 1.5 x upper limit of normal (ULN) OR, if >1.5x ULN, creatinine clearance (CrCl) >= 30 mL/min/1.73 m^2, Total bilirubin <= 1.5 x ULN OR <= 3.0 x ULN in participants with known or suspected Gilbert's syndrome, ALT and AST <= 2.5 x ULN (unless liver metastases are present, then values must be <= 5 x ULN), serologically positive for hepatitis C virus (HCV) are eligible if HCV viral load is undetectable, serologically positive for human immunodeficiency virus (HIV) are eligible if they are on stable antiretroviral therapy for at least 4 weeks before treatment initiation, have no reported opportunistic infections or Castleman s disease within 12 months prior to treatment initiation, have a viral load that is undetectable by quantitative polymerase chain reaction (PCR) and CD4 count >= 200 cells per cubic millimeter, participants with brain metastasis are eligible if at least 4 weeks status post radiotherapy or surgery before treatment initiation with no evidence of progression or associated symptoms
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 years
Awards & highlights
Study Summary
This trial tests 2 drugs to treat kidney cancer in people aged 18+. Participants take pills and get injections, have tests and scans. Follow-up visits and scans are done for up to 6 years.
Who is the study for?
Adults with advanced kidney cancer, either clear cell renal cell carcinoma (ccRCC) after checkpoint inhibitor therapy and possibly VEGF antagonist treatment, or papillary renal cell carcinoma (pRCC), which may be untreated. Participants need at least one measurable tumor lesion, good physical condition, adequate blood counts and organ function. They must agree to use effective contraception and not breastfeed during the trial.Check my eligibility
What is being tested?
The trial is testing a combination of two drugs: Sasanlimab (an injection) given once each cycle, and Palbociclib (a pill) taken daily for 21 days in each 28-day cycle. The study aims to evaluate their effectiveness in treating kidney cancers over cycles lasting up to two years with follow-ups extending up to six years.See study design
What are the potential side effects?
Potential side effects include reactions at the injection site for Sasanlimab, liver issues from both drugs, fatigue, nausea or other digestive problems from Palbociclib. Blood count changes could also occur. Side effects can vary between individuals.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Select...
Your kidneys and liver are working well, and you do not have certain viral infections. If you have brain metastasis, you must have completed treatment at least 4 weeks ago with no signs of progression.
Select...
My kidney cancer is confirmed as clear cell (ccRCC) or papillary (pRCC).
Select...
I have advanced kidney cancer with at least one tumor that can be measured.
Select...
I have ccRCC and have been treated with checkpoint inhibitors and VEGF pathway antagonists.
Select...
I am fully active and can carry on all my pre-disease activities without restriction.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Phase I: To determine RP2D of palbociclib in combination with sasanlimab
Phase II: Objective response rate (ORR)
Secondary outcome measures
Disease Control Rate (DCR) defined as PR + CR+ SD in participants re-treated with the study drug combination by RECIST 1.1
overall survival (OS)
progression-free survival (PFS)
+1 moreTrial Design
2Treatment groups
Experimental Treatment
Group I: 2/Phase IIExperimental Treatment2 Interventions
Sasanlimab and palbociclib at the dose determined in Phase I (RP2D)
Group II: 1/ Phase IExperimental Treatment2 Interventions
Sasanlimab and deescalating doses of palbociclib
Find a Location
Who is running the clinical trial?
National Cancer Institute (NCI)Lead Sponsor
13,672 Previous Clinical Trials
40,926,341 Total Patients Enrolled
Ramaprasad Srinivasan, M.D.Principal InvestigatorNational Cancer Institute (NCI)
5 Previous Clinical Trials
125 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have had cancer other than kidney cancer in the last 2 years.I have had a bone marrow or organ transplant in the past.I have or had hepatitis B.I am 18 years old or older.I have a history of lung disease or tuberculosis.I am taking high doses of steroids or specific immune system medications.Your kidneys and liver are working well, and you do not have certain viral infections. If you have brain metastasis, you must have completed treatment at least 4 weeks ago with no signs of progression.My kidney cancer is confirmed as clear cell (ccRCC) or papillary (pRCC).Your blood counts need to be within normal range, with a minimum number of white blood cells, red blood cells, and platelets.I have pRCC and may or may not have received treatment for it.I haven't had treatments for kidney cancer in the last 4 weeks or 5 half-lives.I have had more than two treatments for cancer that has spread.My surgical wound reopened after a previous operation.I do not have chronic diarrhea, IBD, or conditions affecting drug absorption.I have not taken any herbal supplements in the last 14 days.I have advanced kidney cancer with at least one tumor that can be measured.I have ccRCC and have been treated with checkpoint inhibitors and VEGF pathway antagonists.I am fully active and can carry on all my pre-disease activities without restriction.You have had allergic reactions to similar drugs in the past.I've had severe side effects from immunotherapy before.I haven't taken strong CYP3A affecting drugs in the last 21 days or 5 half-lives.You currently have an autoimmune disease that is not well controlled.
Research Study Groups:
This trial has the following groups:- Group 1: 1/ Phase I
- Group 2: 2/Phase II
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are participants still able to enroll in this research project?
"According to clinicaltrials.gov, the recruiting process for this trial has been deactivated since December 29th 2022. Although recruitment is not taking place at present, there are over 2500 other medical studies that have opened their doors to enrolment."
Answered by AI
What outcomes is this investigation seeking to accomplish?
"The primary goal of this 28-day clinical trial is to assess the objective response rate (ORR) of the combination. Additionally, progression-free survival (PFS), safety of the combination and overall survival (OS) will be monitored as secondary outcomes. These data points will be gathered through regular imaging scans every 8 (+/-1) weeks for 32 weeks followed by 12 (+/- 1) week intervals until either disease progression or 6 years after enrollment are recorded. Toxicities or adverse events must also be documented from Day 1 up to 90 days following intervention administration where applicable - only serious side effects related to study interventions reported beyond that window."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger